US20100081788A1 - Process for the Preparation of Pramlintide - Google Patents

Process for the Preparation of Pramlintide Download PDF

Info

Publication number
US20100081788A1
US20100081788A1 US12/553,567 US55356709A US2010081788A1 US 20100081788 A1 US20100081788 A1 US 20100081788A1 US 55356709 A US55356709 A US 55356709A US 2010081788 A1 US2010081788 A1 US 2010081788A1
Authority
US
United States
Prior art keywords
asn
tbu
trt
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/553,567
Inventor
Tsung Yu Hsiao
Jin Guc Ding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scinopharm Taiwan Ltd
Original Assignee
Scinopharm Taiwan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scinopharm Taiwan Ltd filed Critical Scinopharm Taiwan Ltd
Priority to US12/553,567 priority Critical patent/US20100081788A1/en
Assigned to SCINOPHARM TAIWAN LTD. reassignment SCINOPHARM TAIWAN LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HSIAO, TSUNG YU, DING, JIN GUO
Publication of US20100081788A1 publication Critical patent/US20100081788A1/en
Priority to US13/113,354 priority patent/US20110288235A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids

Definitions

  • the present invention relates to the efficient commercial synthesis for the making of pramilintide, a synthetic analog of human amylin which is a peptide hormone.
  • Pramilintide is indicated to treat type 1 and type 2 diabetics who use insulin.
  • the process for making pramilintide substantially comprises the syntheses of various fragments of the polypeptide and the coupling of the fragments to produce pramilintide.
  • pramlintide is disclosed in U.S. Pat. No. 5,686,411, which is herein incorporated in its entirety by reference.
  • Pramlintide is known to be prepared by solid phase synthesis that successively adds the desired amino acid to a growing peptide chain.
  • an ⁇ -N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin support are reacted at room temperature in an inert solvent in the presence of coupling agents such as dicyclohexylcarbodiimide 1-hydroxybenzotriazole in the presence of a base.
  • the ⁇ -N-carbamoyl protecting group is removed from the resultant peptide with a reagent such as trifluoroacetic acid or piperidine, and the coupling reaction repeated with the next desired N-protected amino acid.
  • a reagent such as trifluoroacetic acid or piperidine
  • Suitable N-protecting groups are known in the art, with t-butyloxycarbonyl herein preferred.
  • U.S. Pat. No. 5,424,394 provides a classical stepwise approach for the synthesis of amylin and amylin analogues. Single amino acid residues are covalently coupled to a growing peptide chain which is covalently linked to a solid resin support. The synthetic route is very lengthy and inefficiently since several coupling and deprotected steps have to be repeated.
  • the present invention provides a more efficient synthesis of pramlintide and the yield and purity of final product will be improved in view of the prior art.
  • the present invention provides for an efficient process for making pramlinitide that is high in yield and scalable for commercial production.
  • the process comprises the stepwise synthesis of amino acid segments, and the coupling together of these segments to produce pramlinitide.
  • the present invention provides for four novel intermediate amino acid segments for the preparation of pramlintide.
  • the four segments are synthesized in solid phase synthesis and the coupling reaction is performed in solution phase.
  • the segments are produced by coupling a protected designated amino acid to a growing peptide chain that is covalently linked to an insoluble solid resin support.
  • the “protected designated amino acid” refers to single amino acid (having protected sidechains and amino termini) which generally proceed from the carboxy-terminal end to the amino-terminal end to give a peptide of specified sequence.
  • a “growing peptide chain” refers to a general cycle of synthesis comprising deprotection of the ⁇ -amino group of the resin-bound amino acid or peptide, followed by reaction (coupling) of the free ⁇ -amino group with some carboxyl-activated form of the next ⁇ -amino protected amino acid to form a peptide linkage and to give a support-bound peptide.
  • the Fmoc protecting group was removed by treatment with 20% piperidine in DMF twice for 10 min and 30 min, respectively.
  • the second amino acid (Fmoc-Cys (Acm)-OH) was introduced to start the first coupling step.
  • the Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU (O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate)/HOBt (N-Hydroxybenzotriazole)/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h.
  • the peptide was cleaved from the peptide on resin (8 g) prepared as described above, using 20% TFE solution in DCM for 2 h.
  • the peptide solution was solvent replaced by MeOH and concentrated (30 mL).
  • the concentrated residue was cooled and the product was precipitated by adding water (30 mL).
  • the precipitated product was separated by filtration and washed with mixed solvent of MeOH/water (10 mL/10 mL) twice to give Boc-Lys(Boc)-Cys(Acm)-Asn(Trt)-Thr(tBu)-Ala-Thr(tBu)-Cys(Acm)-Ala-OH(S1a).
  • the second amino acid (Fmoc-His(Trt)-OH) was introduced to start the first coupling step.
  • the Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU/HOBt/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h. Completion of the coupling was indicated by a Kaiser test.
  • the Fmoc protecting group on the ⁇ -amine was removed with 20% piperidine in DMF twice for 10 min and 30 min, respectively. These steps were repeated each time with another amino acid according to peptide sequence. All amino acids used were Fmoc-N ⁇ protected.
  • Trifunctional amino acids were side chain protected as follows: Asn(Trt)-OH, Arg(Pbf)-OH, Gln(Trt)-OH and Thr(tBu)-OH. Three equivalents of the activated amino acids were employed in the coupling reactions. At the end of the synthesis the growing peptide on resin was washed with DMF, MeOH followed by MTBE, and dried under vacuum to give dry peptide on resin.
  • the peptide was cleaved from the peptide on resin (24 g) prepared as described above, using 20% TFE solution in DCM for 2 h.
  • the peptide solution was solvent replaced by MeOH and concentrated (50 mL).
  • the product was absolutely precipitated by adding cool MeOH (50 mL) to the concentrated residue.
  • the product was separated by filtration and washed with cool MeOH (20 mL) twice to give S2 (Fmoc-Thr(tBu)-Gln(Trt)-Arg(Pbf)-Leu-Ala-Asn(Trt)-Phe-Leu-Val-His(Trt)-Ser(tBu)-O H, 12 g).
  • the Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU/HOBt/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h. Completion of the coupling was indicated by a Kaiser test. After washing of the resin, the Fmoc protecting group on the ⁇ -amine was removed with 20% piperidine in DMF twice for 10 min and 30 min, respectively. These steps were repeated each time with another amino acid according to peptide sequence. All amino acids used were Fmoc-N ⁇ protected. Trifunctional amino acids were side chain protected as follows: Ser(tBu)-OH, and Asn(Trt)-OH. Three equivalents of the activated amino acids were employed in the coupling reactions. At the end of the synthesis the growing peptide on resin was washed with DMF, MeOH followed by MTBE, and dried under vacuum to give dry peptide on resin.
  • the peptide was cleaved from the growing peptide on resin (10 g) prepared as described above, using 1% TFA solution in DCM for 1.5 h. After neutralizing with Pyridine the peptide solution was concentrated (15 mL). The product was precipitated by adding the concentrated residue into Heptanes (50 mL). The product was separated by filtration and washed with mixed solvent of DCM/Heptanes (1 mL/3 mL) three times to give S3 (Fmoc-Ser(tBu)-Asn(Trt)-Asn(Trt)-Phe-Gly-Pro-Ile-Leu-Pro-Pro-OH, 5.2 g).
  • the second amino acid (Fmoc-Asn(Trt)-OH) was introduced to start the first coupling step.
  • the Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU/HOBt/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h. Completion of the coupling was indicated by a Kaiser test.
  • the Fmoc protecting group on the ⁇ -amine was removed with 20% piperidine in DMF twice for 10 min and 30 min, respectively. These steps were repeated each time with another amino acid according to peptide sequence. All amino acids used were Fmoc-N ⁇ protected.
  • Trifunctional amino acids were side chain protected as follows: Ser(tBu)-OH, Asn(Trt)-OH and Thr(tBu)-OH. Three equivalents of the activated amino acids were employed in the coupling reactions. At the end of the synthesis the growing peptide on resin was washed with DMF, MeOH followed by MTBE, and dried under vacuum to give dry peptide on resin.
  • the peptide was cleaved from the peptide on resin (23 g) prepared as described above, using 20% TFE solution in DCM for 2 h.
  • the peptide solution was solvent replaced by MeOH and concentrated (60 mL).
  • the product was precipitated by adding MeOH (50 mL) to the concentrated residue.
  • the product was separated by filtration and washed with MeOH/water (20 mL) twice to give S4 (Fmoc-Thr(tBu)-Asn(Trt)-Val-Gly-Ser(tBu)-Asn(Trt)-Thr(tBu)-OH, 10.6 g)
  • the reaction mixture is warmed to 20 to 30° C. and kept for 15 hr. Diethylamine (DEA) (0.42 Kg; 10.0 eq.) is charged while maintaining the temperature at 25° C.
  • DEA Diethylamine
  • the reaction mixture is stirred at 20 to 30° C. for 2 hr.
  • Ethyl acetate (EA) (7.38 Kg) and softened potable water (SPW) (50.0 Kg) are slowly added to the reaction mixture while maintaining the temperature at 35° C. until the cloud point is observed and held at cloud point for 1 hr. The remained SPW is added while maintaining the temperature at 35° C.
  • the wet cake is purged by nitrogen for 1 hr and dried at 50° C. for 5 hr to get M2 (Thr(tBu)Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr(tBu) Tyr(tBu)-NH 2 ) (about 0.81 Kg).
  • Ethyl(3-dimethylaminopropyl)carbodiimide hydrochloride (0.30 Kg; 3.0 eq) is charged into the resulting mixture while maintaining the temperature at 20 to 30° C. and stirred for 3 hr.
  • Ethyl acetate (EA) (5.1 Kg) and SPW (43.6 Kg) are slowly added into the reaction mixture while maintaining the temperature at 35° C. until the cloud point is observed and held at cloud point for 1 hr. The remained SPW is added while maintaining the temperature at 35° C.
  • the solid is filtered and washed by MeOH twice. The wet cake is purged with nitrogen for 1 hr and dried at 50° C.
  • the wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 5 hr to provide M4 (Ser(tBu)Asn(Trt)Asn(Trt)PheGlyProlleLeuProProThr(tBu)Asn(Trt)ValGlySer(tBu) Asn(Trt)Thr(tBu)Tyr(tBu)-NH 2 ) (about 1.32 Kg).
  • M5 (2.16 Kg; 1.0 eq) and dichloromethane (DCM) (28.7 Kg) are charged into a suitable reactor under nitrogen. Then piperidine (0.32 Kg; 10.0 eq) is charged while maintaining the temperature at 20 to 30° C. and stirred for 2 hr. Methyl-t-butyl ether (MTBE) (47.9 Kg) is slowly added while maintaining the temperature at 0 to 10° C. until the cloud point is observed and held at cloud point for 1 hr. The remained MTBE is added while maintaining the temperature at 0 to 10° C.
  • MTBE Methyl-t-butyl ether
  • the wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 5 hr to provide M6 (Thr(tBu)Gln(Trt)Arg(Pbf)LeuAlaAsn(Trt)Phe LeuValHis(Trt)Ser(tBu)Ser(tBu)Asn(Trt)Asn(Trt)PheGlyProlleLeuProProThr(tBu) Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr(tBu)Tyr(tBu)-NH 2 ) (about 1.87 Kg).
  • 1-hydroxy-7-azabenzotriazole (0.14 Kg; 3.0 eq.) are charged into a suitable reactor under nitrogen.
  • M7 (2.09 Kg) is charged into reactor I under nitrogen.
  • the solid is kept at temperature 0 to 10° C.
  • SPW 0.52 Kg
  • TEA trifluoroacetic acid
  • TIS triisopropylsilane
  • the mixed solution in reactor II is cooled to 0 to 10° C. and charged into reactor I at 25° C.
  • the reaction mixture is stirred at 20-30° C. for 3 hr.
  • the reaction mixture is cooled to 0 to 10° C. and the pre-cooled (0 to 10° C.) methyl-t-butyl ether (MTBE) (61.85 Kg) is slowly charged at 15° C. and stirred for 1 hr.
  • the solid product is filtered and washed with methyl-t-butylether (MTBE) twice and tetrahydrofuran (THF) twice.
  • the wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 6 hr to provide pramlintide acetate (about 1.21 Kg).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention provides for an efficient process for making Pramlinitide, as well as novel intermediates for the making of the same.

Description

    RELATED APPLICATIONS
  • This application claims priority from U.S. Provisional Patent Application Ser. No. 61/190,928 which was filed on Sep. 3, 2008. The entire content of which is herein incorporated by reference.
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to the efficient commercial synthesis for the making of pramilintide, a synthetic analog of human amylin which is a peptide hormone. Pramilintide is indicated to treat type 1 and type 2 diabetics who use insulin. The process for making pramilintide substantially comprises the syntheses of various fragments of the polypeptide and the coupling of the fragments to produce pramilintide.
  • 2. Description of the Related Arts
  • The preparation and use of pramlintide is disclosed in U.S. Pat. No. 5,686,411, which is herein incorporated in its entirety by reference. Pramlintide is known to be prepared by solid phase synthesis that successively adds the desired amino acid to a growing peptide chain. Typically, an α-N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin support are reacted at room temperature in an inert solvent in the presence of coupling agents such as dicyclohexylcarbodiimide 1-hydroxybenzotriazole in the presence of a base. The α-N-carbamoyl protecting group is removed from the resultant peptide with a reagent such as trifluoroacetic acid or piperidine, and the coupling reaction repeated with the next desired N-protected amino acid. Suitable N-protecting groups are known in the art, with t-butyloxycarbonyl herein preferred. U.S. Pat. No. 5,424,394 provides a classical stepwise approach for the synthesis of amylin and amylin analogues. Single amino acid residues are covalently coupled to a growing peptide chain which is covalently linked to a solid resin support. The synthetic route is very lengthy and inefficiently since several coupling and deprotected steps have to be repeated. The present invention provides a more efficient synthesis of pramlintide and the yield and purity of final product will be improved in view of the prior art.
  • SUMMARY OF THE INVENTION
  • The present invention provides for an efficient process for making pramlinitide that is high in yield and scalable for commercial production. The process comprises the stepwise synthesis of amino acid segments, and the coupling together of these segments to produce pramlinitide. The present invention provides for four novel intermediate amino acid segments for the preparation of pramlintide. In a preferable embodiment of the invention, the four segments are synthesized in solid phase synthesis and the coupling reaction is performed in solution phase. Preferably, the segments are produced by coupling a protected designated amino acid to a growing peptide chain that is covalently linked to an insoluble solid resin support. The “protected designated amino acid” refers to single amino acid (having protected sidechains and amino termini) which generally proceed from the carboxy-terminal end to the amino-terminal end to give a peptide of specified sequence. A “growing peptide chain” refers to a general cycle of synthesis comprising deprotection of the α-amino group of the resin-bound amino acid or peptide, followed by reaction (coupling) of the free α-amino group with some carboxyl-activated form of the next α-amino protected amino acid to form a peptide linkage and to give a support-bound peptide.
  • DETAILED DESCRIPTION OF THE INVENTION
  • To assist in understanding the present invention, the following examples are included which describe the results of a series of experiments. The following examples relating to this invention should not, of course, be construed as specifically limiting the invention. Such variations of the invention, now known or later developed, which would be within the purview of one skilled in the art are considered to fall within the scope of the present invention as hereinafter claimed.
  • Example 1 Preparation of Protected Fragment S1 (1-8)
  • Figure US20100081788A1-20100401-C00001
  • Synthesis of the protected peptide was carried out by a stepwise Fmoc SPPS (solid phase peptide synthesis) procedure starting with loading a Fmoc-Ala-OH to 2-Cl-Trt-Cl resin (CTC resin). The CTC resin (4 g) after washing was stirred with a solution of Fmoc-Ala-OH (1.49 g) in DMF in the presence of diisopropylethylamine (DIEA, 2.3 g) for 1.5 h. The resin was further capped by treatment with mixed solvent of 5:4:1 volume ratio of DCM/MeOH/DIEA for 0.5 h. After washing of the resin the Fmoc protecting group was removed by treatment with 20% piperidine in DMF twice for 10 min and 30 min, respectively. After washing of residual reagents the second amino acid (Fmoc-Cys (Acm)-OH) was introduced to start the first coupling step. The Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU (O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate)/HOBt (N-Hydroxybenzotriazole)/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h. Completion of the coupling was indicated by a Kaiser test. After washing of the resin, the Fmoc protecting group on the α-amine was removed with 20% piperidine in DMF twice for 10 min and 30 min, respectively. These steps were repeated each time with another amino acid according to peptide sequence. All amino acids used were Fmoc-Nα protected except the last amino acid in the sequence, Boc-Lys(Boc)-OH. Trifunctional amino acids were side chain protected as follows: Lys(Boc)-OH, Asn(Trt)-OH, Thr(tBu)-OH. Three equivalents of the activated amino acids were employed in the coupling reactions. At the end of the synthesis the peptide resin was washed with DMF, MeOH followed by MTBE, and dried under vacuum to give dry peptide on resin.
  • The peptide was cleaved from the peptide on resin (8 g) prepared as described above, using 20% TFE solution in DCM for 2 h. The peptide solution was solvent replaced by MeOH and concentrated (30 mL). The concentrated residue was cooled and the product was precipitated by adding water (30 mL). The precipitated product was separated by filtration and washed with mixed solvent of MeOH/water (10 mL/10 mL) twice to give Boc-Lys(Boc)-Cys(Acm)-Asn(Trt)-Thr(tBu)-Ala-Thr(tBu)-Cys(Acm)-Ala-OH(S1a).
  • 10 g S1a was dissolved in a mixed solvent of DMF/pyridine/MeOH, and then add a solution with I2 in DMF/MeOH during 2.5 h. After 1 h, the mixture was quenched with Vitamin C/ammonium acetate in water. More water was added to gain crude S1. Further purification was carried out by silica gel to give S1
  • Figure US20100081788A1-20100401-C00002
  • Example 2 Preparation of Protected Fragment S2 (9-19) Fmoc-Thr(tBu)-Gln(Trt)-Arg(Pbf)-Leu-Ala-Asn(Trt)-Phe-Leu-Val-His(Trt)-Ser(tBu)-OH
  • Synthesis of the protected peptide was carried out by a stepwise Fmoc SPPS (solid phase peptide synthesis) procedure starting with loading a Fmoc-Ser(tBu)-OH to 2-Cl-Trt-Cl resin (CTC resin). The CTC resin (10 g) after washing was stirred with a solution of Fmoc-Ser(tBu)-OH (4.6 g) in DMF in the presence of diisopropylethylamine (2.3 g) for 1.5 h. After washing of the resin the Fmoc protecting group was removed by treatment with 20% piperidine in DMF twice for 10 min and 30 min, respectively. After washing of residual reagents the second amino acid (Fmoc-His(Trt)-OH) was introduced to start the first coupling step. The Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU/HOBt/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h. Completion of the coupling was indicated by a Kaiser test. After washing of the resin, the Fmoc protecting group on the α-amine was removed with 20% piperidine in DMF twice for 10 min and 30 min, respectively. These steps were repeated each time with another amino acid according to peptide sequence. All amino acids used were Fmoc-Nα protected. Trifunctional amino acids were side chain protected as follows: Asn(Trt)-OH, Arg(Pbf)-OH, Gln(Trt)-OH and Thr(tBu)-OH. Three equivalents of the activated amino acids were employed in the coupling reactions. At the end of the synthesis the growing peptide on resin was washed with DMF, MeOH followed by MTBE, and dried under vacuum to give dry peptide on resin.
  • The peptide was cleaved from the peptide on resin (24 g) prepared as described above, using 20% TFE solution in DCM for 2 h. The peptide solution was solvent replaced by MeOH and concentrated (50 mL). The product was absolutely precipitated by adding cool MeOH (50 mL) to the concentrated residue. The product was separated by filtration and washed with cool MeOH (20 mL) twice to give S2 (Fmoc-Thr(tBu)-Gln(Trt)-Arg(Pbf)-Leu-Ala-Asn(Trt)-Phe-Leu-Val-His(Trt)-Ser(tBu)-O H, 12 g).
  • Example 3 Preparation of Protected Fragment S3 (20-29) Fmoc-Ser(tBu)-Asn(Trt)-Asn(Trt)-Phe-Gly-Pro-Ile-Leu-Pro-Pro-OH
  • Synthesis of the protected peptide was carried out by a stepwise Fmoc SPPS (solid phase peptide synthesis) procedure starting with loading a Fmoc-Pro-OH to 2-Cl-Trt-Cl resin (CTC resin). The CTC resin (3 g) after washing was stirred with a solution of Fmoc-Pro-OH (1.2 g) in DMF in the presence of diisopropylethylamine (2.3 g) for 1.5 h. After washing of the resin the Fmoc protecting group was removed by treatment with 20% piperidine in DMF twice for 10 min and 30 min, respectively. After washing of residual reagents the second amino acid (Fmoc-Pro-OH) was introduced to start the first coupling step. The Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU/HOBt/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h. Completion of the coupling was indicated by a Kaiser test. After washing of the resin, the Fmoc protecting group on the α-amine was removed with 20% piperidine in DMF twice for 10 min and 30 min, respectively. These steps were repeated each time with another amino acid according to peptide sequence. All amino acids used were Fmoc-Nα protected. Trifunctional amino acids were side chain protected as follows: Ser(tBu)-OH, and Asn(Trt)-OH. Three equivalents of the activated amino acids were employed in the coupling reactions. At the end of the synthesis the growing peptide on resin was washed with DMF, MeOH followed by MTBE, and dried under vacuum to give dry peptide on resin.
  • The peptide was cleaved from the growing peptide on resin (10 g) prepared as described above, using 1% TFA solution in DCM for 1.5 h. After neutralizing with Pyridine the peptide solution was concentrated (15 mL). The product was precipitated by adding the concentrated residue into Heptanes (50 mL). The product was separated by filtration and washed with mixed solvent of DCM/Heptanes (1 mL/3 mL) three times to give S3 (Fmoc-Ser(tBu)-Asn(Trt)-Asn(Trt)-Phe-Gly-Pro-Ile-Leu-Pro-Pro-OH, 5.2 g).
  • Example 4 Preparation of Protected Fragment S4 (30-36) Fmoc-Thr(tBu)-Asn(Trt)-Val-Gly-Ser(tBu)-Asn(Trt)-Thr(tBu)-OH
  • Synthesis of the protected peptide was carried out by a stepwise Fmoc SPPS (solid phase peptide synthesis) procedure starting with loading a Fmoc-Thr(tBu)-OH to 2-Cl-Trt-Cl resin (CTC resin). The CTC resin (10 g) after washing was stirred with a solution of Fmoc-Thr(tBu)-OH (4.8 g) in DMF in the presence of diisopropylethylamine (2.3 g) for 1.5 h. After washing of the resin the Fmoc protecting group was removed by treatment with 20% piperidine in DMF twice for 10 min and 30 min, respectively. After washing of residual reagents the second amino acid (Fmoc-Asn(Trt)-OH) was introduced to start the first coupling step. The Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU/HOBt/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h. Completion of the coupling was indicated by a Kaiser test. After washing of the resin, the Fmoc protecting group on the α-amine was removed with 20% piperidine in DMF twice for 10 min and 30 min, respectively. These steps were repeated each time with another amino acid according to peptide sequence. All amino acids used were Fmoc-Nα protected. Trifunctional amino acids were side chain protected as follows: Ser(tBu)-OH, Asn(Trt)-OH and Thr(tBu)-OH. Three equivalents of the activated amino acids were employed in the coupling reactions. At the end of the synthesis the growing peptide on resin was washed with DMF, MeOH followed by MTBE, and dried under vacuum to give dry peptide on resin.
  • The peptide was cleaved from the peptide on resin (23 g) prepared as described above, using 20% TFE solution in DCM for 2 h. The peptide solution was solvent replaced by MeOH and concentrated (60 mL). The product was precipitated by adding MeOH (50 mL) to the concentrated residue. The product was separated by filtration and washed with MeOH/water (20 mL) twice to give S4 (Fmoc-Thr(tBu)-Asn(Trt)-Val-Gly-Ser(tBu)-Asn(Trt)-Thr(tBu)-OH, 10.6 g)
  • Example 5 Coupling and De-Fmoc Reaction
  • S4 (FmocThr(tBu)Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr(tBu)OH) (1.0 kg; 1.0 Eq.), H-Tyr(tBu)-NH2 (0.45 Kg; 3.0 eq.) and 1-hydroxy-7-azabenzotriazole (HOAt) (0.26 Kg; 3.0 eq) are charged into a suitable reactor under nitrogen. 1-methyl-2-pyrrolidinone (NMP) (20.7 Kg) is charged and stirred for 0.5 hr. The resulting mixture is cooled to 0 to 10° C. Then the solution of N,N-diisopropylcarbodiimide (DIC) (0.24 Kg; 3.0 eq) and 1-methyl-2-pyrrolidinone (NMP) (10.3 Kg) is dropped into the cooled resulting mixture for 1 hr while maintaining the temperature at 0 to 10° C.
  • The reaction mixture is warmed to 20 to 30° C. and kept for 15 hr. Diethylamine (DEA) (0.42 Kg; 10.0 eq.) is charged while maintaining the temperature at 25° C. The reaction mixture is stirred at 20 to 30° C. for 2 hr. Ethyl acetate (EA) (7.38 Kg) and softened potable water (SPW) (50.0 Kg) are slowly added to the reaction mixture while maintaining the temperature at 35° C. until the cloud point is observed and held at cloud point for 1 hr. The remained SPW is added while maintaining the temperature at 35° C. The solid is filtered and washed with mixed solvent MeOH/SPW=1/1 twice and n-heptane twice. The wet cake is purged by nitrogen for 1 hr and dried at 50° C. for 5 hr to get M2 (Thr(tBu)Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr(tBu) Tyr(tBu)-NH2) (about 0.81 Kg).
  • Example 6 Coupling Reaction
  • M2 (0.81 Kg; 1.0 eq), S3 (Fmoc-Ser(tBu)Asn(Trt)Asn(Trt)PheGlyProlleLeu ProProOH) (0.85 Kg; 0.9 eq) and 1-hydroxy-7-azabenzotriazole (HOAt) (0.21 Kg; 3.0 eq) are charged into a suitable reactor under nitrogen. Then 1-methyl-2-pyrrolidinone (NMP) (16.7 Kg) is charged and stirred for 0.5 hr. The resulting mixture is cooled to 0 to 10° C.
  • Ethyl(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (0.30 Kg; 3.0 eq) is charged into the resulting mixture while maintaining the temperature at 20 to 30° C. and stirred for 3 hr. Ethyl acetate (EA) (5.1 Kg) and SPW (43.6 Kg) are slowly added into the reaction mixture while maintaining the temperature at 35° C. until the cloud point is observed and held at cloud point for 1 hr. The remained SPW is added while maintaining the temperature at 35° C. The solid is filtered and washed by MeOH twice. The wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 5 hr to get M3 (FmocSer(tBu)Asn(Trt)Asn(Trt)PheGlyProlleLeuProProThr(tBu)Asn(Trt)ValGly Ser(tBu)Asn(Trt)Thr(tBu)Tyr(tBu)-NH2) (about 1.56 Kg).
  • Example 7 DeFmoc Reaction
  • M3 (1.56 Kg; 1.0 eq) and dichloromethane (DCM) (12.5 Kg) are charged into a suitable reactor. Then piperidine (0.60 Kg; 15.0 eq) is charged while maintaining the temperature at 20 to 30° C. and stirred for 2 hr. Methyl-t-butyl ether (MTBE) (34.7 Kg) is slowly added while maintaining the temperature at 30° C. until the cloud point is observed and held at cloud point for 1 hr. The remained MTBE is added while maintaining the temperature at 30° C. The product is filtered and washed with mixed solvent of MeOH/SPW=1/1 twice and methyl-t-butyl ether (MTBE) twice. The wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 5 hr to provide M4 (Ser(tBu)Asn(Trt)Asn(Trt)PheGlyProlleLeuProProThr(tBu)Asn(Trt)ValGlySer(tBu) Asn(Trt)Thr(tBu)Tyr(tBu)-NH2) (about 1.32 Kg).
  • Example 8 Coupling Reaction
  • M4 (1.32 Kg; 1.0 eq), S2 (FmocThr(tBu)Gln(Trt)Arg(Pbf)LeuAlaAsn(Trt) PheLeuValHis(Trt)Ser(tBu)OH) (1.03 Kg; 0.95 eq) and 1-hydroxy-7-azabenzotriazole (HOAt) (0.17 Kg; 3.0 eq) are charged into a suitable reactor under nitrogen. Then 1-methyl-2-pyrrolidinone (NMP) (27.17 Kg) is charged and stirred for 0.5 hr. The resulting mixture is cooled to 0 to 10° C.
  • The solution of N,N-diisopropylcarbodiimide (DIC) (0.16 Kg; 3.0 eq) and 1-methyl-2-pyrrolidinone (NMP) (6.80 Kg) is dropped to the cooled resulting mixture for 1 hr while maintaining the temperature at 0 to 10° C. The reaction mixture is warmed to 20 to 30° C. and kept for 15 hr. Ethyl acetate (EA) (9.47 Kg) is charged into the reaction mixture. Mixed solvent of MeOH/SPW=1/1 (86.8 Kg) is slowly added while maintaining the temperature at 35° C. until the cloud point is observed and held at cloud point for 1 hr. The remained SPW is added while maintaining the temperature at 35° C. The solid is filtered and washed by mixed solvent of MeOH/SPW=4/1. The wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 5 hr to provide M5 (FmocThr(tBu)Gln(Trt)Arg(Pbf)LeuAlaAsn(Trt)PheLeuValHis(Trt)Ser(tBu) Ser(tBu)Asn(Trt)Asn(Trt)PheGlyProlleLeuProProThr(tBu)Asn(Trt)ValGly Ser(tBu)Asn(Trt)Thr(tBu)Tyr(tBu)-NH2) (about 2.16 Kg)
  • Example 9 De-Fmoc Reaction
  • M5 (2.16 Kg; 1.0 eq) and dichloromethane (DCM) (28.7 Kg) are charged into a suitable reactor under nitrogen. Then piperidine (0.32 Kg; 10.0 eq) is charged while maintaining the temperature at 20 to 30° C. and stirred for 2 hr. Methyl-t-butyl ether (MTBE) (47.9 Kg) is slowly added while maintaining the temperature at 0 to 10° C. until the cloud point is observed and held at cloud point for 1 hr. The remained MTBE is added while maintaining the temperature at 0 to 10° C. The product is filtered and washed with mixed solvent of MeOH/SPW=4/1 twice and methyl-t-butyl ether (MTBE) twice. The wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 5 hr to provide M6 (Thr(tBu)Gln(Trt)Arg(Pbf)LeuAlaAsn(Trt)Phe LeuValHis(Trt)Ser(tBu)Ser(tBu)Asn(Trt)Asn(Trt)PheGlyProlleLeuProProThr(tBu) Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr(tBu)Tyr(tBu)-NH2) (about 1.87 Kg).
  • Example 10 Coupling Reaction
  • M6 (1.87 Kg; 1.0 eq.), S1
  • Figure US20100081788A1-20100401-C00003
  • and 1-hydroxy-7-azabenzotriazole (HOAt) (0.14 Kg; 3.0 eq.) are charged into a suitable reactor under nitrogen. 1-Methyl-2-pyrrolidinone (NMP) (19.3 Kg) is charged and stirred for 0.5 hr. The resulting mixture is cooled to 0 to 10° C.
  • The solution of N,N-diisopropylcarbodiimide (DIC) (0.13 Kg; 3.0 eq.) and 1-methyl-2-pyrrolidinone (NMP) (9.63 Kg) is dropped to the cooled resulting mixture for 1 hr while maintaining the temperature at 0 to 10° C. The reaction mixture is kept at 0 to 10° C. for 0.5 hr, followed by warmed to 20 to 30° C. and stirred for 17 hr. Ethyl acetate (EA) (8.39 Kg) is charged into the reaction mixture. SPW (74.6 Kg) is slowly added while maintaining the temperature at 35° C. until the cloud point is observed and held at cloud point for 1 hr. The remained SPW is added while maintaining the temperature at 35° C. for 2 hr. The solid is filtered and washed with mixed solvent of MeOH/SPW=4/1 three times.
  • The wet cake is purged with nitrogen for 1 hr and dried at 30° C. to get M7 (Boc-S1S2S3S4Try(tBu)NH2) (about 2.09 Kg).
  • Example 11 Deblocking Reaction
  • M7 (2.09 Kg) is charged into reactor I under nitrogen. The solid is kept at temperature 0 to 10° C. SPW (0.52 Kg), trifluoroacetic acid (TEA) (29.38 Kg), and triisopropylsilane (TIS) (0.47 Kg) are charged into reactor II under nitrogen.
  • The mixed solution in reactor II is cooled to 0 to 10° C. and charged into reactor I at 25° C. The reaction mixture is stirred at 20-30° C. for 3 hr.
  • The reaction mixture is cooled to 0 to 10° C. and the pre-cooled (0 to 10° C.) methyl-t-butyl ether (MTBE) (61.85 Kg) is slowly charged at 15° C. and stirred for 1 hr. The solid product is filtered and washed with methyl-t-butylether (MTBE) twice and tetrahydrofuran (THF) twice. The wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 6 hr to provide pramlintide acetate (about 1.21 Kg).

Claims (20)

1. A process for the preparation of pramlintide of formula (I):
Figure US20100081788A1-20100401-C00004
comprising:
(a) reacting a protected side chain peptide of formula (II):
(SEQ ID NO: 4) P1-Thr(P2)-Asn(P2)-Val-Gly-Ser(P2)-Asn(P2)-Thr (P2)-OH (II)
wherein P1 and P2 are protecting groups, with H-Tyr(P2)-NH2 to yield a protected side chain peptide of formula (III)
(SEQ ID NO: 5) P1-Thr(P2)-Asn(P2)-Val-Gly-Ser(P2)-Asn(P2)-Thr (P2)-Tyr(P2)-NH2 (III);
(b) removing the terminal P1 protecting group and reacting with a protecting side chain peptide of formula (IV)
(SEQ ID NO: 3) P1-Ser(P2)-Asn(P2)-Asn(P2)-Phe-Gly-Pro-Ile-Leu- Pro-Pro-OH (IV)
wherein P1 and P2 are as defined above, to yield a protected side chain peptide of formula (V)
(SEQ ID NO: 6) P-Ser(P2)-Asn(P2)-Asn(P2)-Phe-Gly-Pro-Ile-Leu-Pro- Pro-Thr(P2)-Asn(P2)-Val-Gly-Ser(P2)-Asn(P2)-Thr (P2)-Tyr(P2)-NH2 (V);
(c) removing the terminal P protecting group and reacting with a protecting side chain peptide of formula (VI)
(SEQ ID NO: 2) P1-Thr(P2)-Gln(P2)-Arg(P2)-Leu-Ala-Asn(P2)-Phe- Leu-Val-His(P2)-Ser(P2)-OH (VI)
wherein P1 and P2 are as defined above, to yield a protected side chain peptide of formula (VII)
(SEQ ID NO: 7) P1-Thr(P2)-Gln(P2)-Arg(P2)-Leu-Ala-Asn(P2)-Phe- Leu-Val-His(P2)-Ser(P2)-Ser(P2)-Asn(P2)-Asn(P2)- Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr(P2)-Asn(P2)-Val- Gly-Ser(P2)-Asn(P2)-Thr(P2)-Tyr(P2)-NH2 (VII);
(d) removing the terminal P protecting group and reacting a protecting side chain peptide of formula (VIII)
Figure US20100081788A1-20100401-C00005
wherein P1 and P2 are as defined above, to yield a protected side chain pramlintide of formula (IX)
Figure US20100081788A1-20100401-C00006
(e) deprotecting the side chains and terminal amino protecting group to yield pramlintide (I).
2. The process of claim 1, wherein P1 is Fmoc or Boc.
3. The process of claim 1, wherein P1 in step (d) is Boc.
4. The process of claim 1, wherein P2 is selected from tBu, Trt and Pbf
5. The process of claim 1, wherein steps (a) to (e) are performed in solution.
6. The process of claim 1, wherein at least one of the coupling reaction of steps a) to d) is accomplished with the reagent selected from 1-hydroxy-7-azabenzotriazole, 1-methyl-2-pyrrolidinone, ethyl(3-dimethylaminopropyl)carbodiimide hydrochloride, N,N-diisopropylcarbodiimide and combinations thereof.
7. The process of claim 1, wherein the deprotecting step is carried out with piperidine when the protecting group is Fmoc or with trifluoroacetic acid when the protecting group is Boc.
8. A protected side chain peptide of formula (III)
(SEQ ID NO: 5) P1-Thr(P2)-Asn(P2)-Val-Gly-Ser(P2)-Asn(P2)-Thr (P2)-Tyr(P2)-NH2 (III)
wherein P1 and P2 are protecting groups.
9. The peptide of claim 8, which is
(SEQ ID NO: 5) Fmoc-Thr(tBu)Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr (tBu)Tyr(tBu)-NH2.
10. The process of making
(SEQ ID NO: 5) Fmoc-Thr(tBu)Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr (tBu)Tyr(tBu)-NH2
by reacting
(SEQ ID NO: 4) Fomc-Thr(tBu)Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr (tBu)-OH
with H-Tyr(tBu)-NH2.
11. The process of claim 10, wherein Fomc-
(SEQ ID NO: 4) Thr(tBu)Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr(tBu)-OH
is produced by solid phase synthesis comprising coupling a protected designated amino acid to a growing peptide chain covalently linked to an insoluble solid resin support to give Fomc-
(SEQ ID NO: 4) Thr(tBu)Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr(tBu)-OH.
12. A protected side chain peptide of formula (IV)
(SEQ ID NO: 3) P1-Ser(P2)-Asn(P2)-Asn(P2)-Phe-Gly-Pro-Ile-Leu- Pro-Pro-OH (IV)
wherein P1 and P2 are protecting groups.
13. The peptide of claim 12, which is
(SEQ ID NO: 3) Fmoc-Ser(tBu)-Asn(Trt)-Asn(Trt)-Phe-Gly-Pro-Ile- Leu-Pro-Pro-OH.
14. The process of making
(SEQ ID NO: 3) Fmoc-Ser(tBu)-Asn(Trt)-Asn(Trt)-Phe-Gly-Pro-Ile- Leu-Pro-Pro-OH,
comprising coupling a protected designated amino acid to a growing peptide chain covalently linked to an insoluble solid resin support to give
(SEQ ID NO: 3) Fmoc-Ser(tBu)-Asn(Trt)-Asn(Trt)-Phe-Gly-Pro-Ile- Leu-Pro-Pro-OH.
15. A protected side chain peptide of formula (VI)
(SEQ ID NO: 2) P1-Thr(P2)-Gln(P2)-Arg(P2)-Leu-Ala-Asn(P2)-Phe- Leu-Val-His(P2)-Ser(P2)-OH (VI)
wherein P1 and P2 are protecting groups.
16. The peptide of claim 15, which is
(SEQ ID NO: 2) Fmoc-Thr(tBu)-Gln(Trt)Arg(Pbf)-Leu-Ala-Asn(Trt)- Phe-Leu-Val-His(Trt)-Ser(tBu)-OH.
17. The process of making
(SEQ ID NO: 2) Fmoc-Thr(tBu)-Gln(Trt)Arg(Pbf)-Leu-Ala-Asn(Trt)- Phe-Leu-Val-His(Trt)-Ser(tBu)-OH,
comprising coupling a protected designated amino acid to a growing peptide chain covalently linked to an insoluble solid resin support to give
(SEQ ID NO: 2) Fmoc-Thr(tBu)-Gln(Trt)Arg(Pbf)-Leu-Ala-Asn(Trt)- Phe-Leu-Val-His(Trt)-Ser(tBu)-OH
and a deprotecting step.
18. A protected side chain peptide of formula (VIII)
Figure US20100081788A1-20100401-C00007
wherein P1 and P2 are protecting groups.
19. The peptide of claim 18, which is
Figure US20100081788A1-20100401-C00008
20. The process of making
Figure US20100081788A1-20100401-C00009
comprising coupling a protected designated amino acid to a growing peptide chain covalently linked to an insoluble solid resin support and selectively deprotecting the cysteine residues and forming an intramolecular disulfide bond between cysteine residues on the peptide chain before cleaving the peptide chain from the solid support to produce
Figure US20100081788A1-20100401-C00010
US12/553,567 2008-09-03 2009-09-03 Process for the Preparation of Pramlintide Abandoned US20100081788A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/553,567 US20100081788A1 (en) 2008-09-03 2009-09-03 Process for the Preparation of Pramlintide
US13/113,354 US20110288235A1 (en) 2008-09-03 2011-05-23 Process for the Preparation of Pramlintide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19092808P 2008-09-03 2008-09-03
US12/553,567 US20100081788A1 (en) 2008-09-03 2009-09-03 Process for the Preparation of Pramlintide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/113,354 Continuation-In-Part US20110288235A1 (en) 2008-09-03 2011-05-23 Process for the Preparation of Pramlintide

Publications (1)

Publication Number Publication Date
US20100081788A1 true US20100081788A1 (en) 2010-04-01

Family

ID=41726391

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/553,567 Abandoned US20100081788A1 (en) 2008-09-03 2009-09-03 Process for the Preparation of Pramlintide
US12/553,482 Expired - Fee Related US8252896B2 (en) 2008-09-03 2009-09-03 Process for making bivalirudin

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/553,482 Expired - Fee Related US8252896B2 (en) 2008-09-03 2009-09-03 Process for making bivalirudin

Country Status (11)

Country Link
US (2) US20100081788A1 (en)
EP (2) EP2349307B1 (en)
JP (2) JP2012502045A (en)
KR (2) KR20110056536A (en)
CN (2) CN102164609A (en)
AR (2) AR073544A1 (en)
AU (2) AU2009288036A1 (en)
CA (2) CA2736113A1 (en)
IL (2) IL211556A0 (en)
TW (2) TW201024316A (en)
WO (2) WO2010028122A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100249370A1 (en) * 2007-06-29 2010-09-30 Lonza Ag Process for the production of pramlintide
CN102180943A (en) * 2010-12-16 2011-09-14 深圳市健元医药科技有限公司 Production process of polypeptide medicament for assisting to reduce blood sugar
CN104861045A (en) * 2014-02-20 2015-08-26 复旦大学 Cyclopeptide compound GG6F and preparation method thereof
USRE46830E1 (en) 2004-10-19 2018-05-08 Polypeptide Laboratories Holding (Ppl) Ab Method for solid phase peptide synthesis

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075983A1 (en) 2008-12-29 2010-07-08 Lonza Braine Sa Process for the production of bivalirudin
WO2013042129A1 (en) * 2011-09-23 2013-03-28 Natco Pharma Limited Improved process for preparation of bivalirudin
WO2014032257A1 (en) * 2012-08-30 2014-03-06 深圳翰宇药业股份有限公司 Method for preparing bivalirudin
SG11201506885UA (en) 2013-03-21 2015-09-29 Sanofi Aventis Deutschland Synthesis of cyclic imide containing peptide products
AU2014234400B2 (en) 2013-03-21 2017-11-16 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
CN111499719B (en) * 2020-03-19 2022-04-08 杭州固拓生物科技有限公司 Method for synthesizing pramlintide
CN118530332A (en) * 2024-07-26 2024-08-23 南京羚诺生物医药技术研究院有限公司 Preparation method of pramlintide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998367A (en) * 1991-03-08 1999-12-07 Amylin Corporation Pramlintide pro H-amylin salts and compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
US5240913A (en) 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
WO1992015317A1 (en) 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues
GB9708918D0 (en) 1997-05-01 1997-06-25 Ppl Therapeutics Scotland Ltd Methods
US6821954B2 (en) * 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
JP4602547B2 (en) * 1998-03-23 2010-12-22 トリメリス,インコーポレーテッド Methods and compositions for peptide synthesis
ATE480561T1 (en) 2004-10-19 2010-09-15 Lonza Ag METHOD FOR SOLID PHASE PEPTIDE SYNTHESIS
JP2008529969A (en) * 2004-10-26 2008-08-07 ロンザ ア−ゲ− S-alkyl-sulfenyl protecting group in solid phase synthesis
CA2618494A1 (en) * 2005-09-14 2007-03-22 Novetide, Ltd. Process for production of bivalirudin
US20070213505A1 (en) * 2006-03-08 2007-09-13 David Epstein Solution Synthesis of Peptide Cell Growth Stimulators
CN101033249B (en) 2006-03-10 2011-05-11 周逸明 Preparation method of synthesizing bivalirudin from solid phase polypeptide
WO2008109079A2 (en) 2007-03-01 2008-09-12 Novetide, Ltd. High purity peptides
JP2010531828A (en) * 2007-06-29 2010-09-30 ロンザ アーゲー Method for producing plumlintide
US20090062511A1 (en) 2007-09-05 2009-03-05 Raghavendracharyulu Venkata Palle Process for the preparation of bivalirudin and its pharmaceutical compositions
WO2010075983A1 (en) * 2008-12-29 2010-07-08 Lonza Braine Sa Process for the production of bivalirudin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998367A (en) * 1991-03-08 1999-12-07 Amylin Corporation Pramlintide pro H-amylin salts and compositions

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46830E1 (en) 2004-10-19 2018-05-08 Polypeptide Laboratories Holding (Ppl) Ab Method for solid phase peptide synthesis
US20100249370A1 (en) * 2007-06-29 2010-09-30 Lonza Ag Process for the production of pramlintide
CN102180943A (en) * 2010-12-16 2011-09-14 深圳市健元医药科技有限公司 Production process of polypeptide medicament for assisting to reduce blood sugar
CN104861045A (en) * 2014-02-20 2015-08-26 复旦大学 Cyclopeptide compound GG6F and preparation method thereof

Also Published As

Publication number Publication date
CA2736113A1 (en) 2010-03-11
EP2334314A4 (en) 2012-03-21
KR20110069048A (en) 2011-06-22
WO2010028122A8 (en) 2014-11-13
AR073360A1 (en) 2010-11-03
KR20110056536A (en) 2011-05-30
IL211556A0 (en) 2011-05-31
JP5788321B2 (en) 2015-09-30
EP2349307A1 (en) 2011-08-03
TW201024316A (en) 2010-07-01
KR101634830B1 (en) 2016-06-29
AU2009288036A1 (en) 2010-03-11
TW201014867A (en) 2010-04-16
WO2010028131A1 (en) 2010-03-11
IL211555A (en) 2014-07-31
CA2736126C (en) 2016-11-29
EP2334314A1 (en) 2011-06-22
EP2349307B1 (en) 2015-03-04
US20100056755A1 (en) 2010-03-04
AU2009288027A2 (en) 2011-11-03
US8252896B2 (en) 2012-08-28
WO2010028122A1 (en) 2010-03-11
EP2349307A4 (en) 2012-03-21
AU2009288027A1 (en) 2010-03-11
IL211555A0 (en) 2011-05-31
AU2009288027B2 (en) 2014-01-16
CN102164608A (en) 2011-08-24
JP2012502044A (en) 2012-01-26
AU2009288036A2 (en) 2011-09-08
TWI395752B (en) 2013-05-11
JP2012502045A (en) 2012-01-26
AR073544A1 (en) 2010-11-17
CN102164609A (en) 2011-08-24
CA2736126A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
US20100081788A1 (en) Process for the Preparation of Pramlintide
US7348404B2 (en) Solid-phase peptide synthesis and agent for use in such synthesis
US20220135639A1 (en) Process for preparing a gip/glp1 dual agonist
US20100249370A1 (en) Process for the production of pramlintide
US20110288235A1 (en) Process for the Preparation of Pramlintide
US20220153804A1 (en) Process of preparation of glucagon-like peptide-1 (glp-1) receptor agonists and their analogs
WO2021070202A1 (en) A method for preparing glp-1 analogue by solid-phase peptide synthesis
US20220324936A1 (en) Process for the manufacture of glucagon
JP2012525348A (en) Insulin secretion-promoting peptide synthesis using solid phase and solution phase combination techniques
CN105408344B (en) Peptide-resin conjugates and uses thereof
EP4436991A1 (en) Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof
US20240116980A1 (en) Compound or salt thereof and preparation method and application of same
US20100137561A1 (en) Process for preparing therapeutic peptide
WO2020047994A1 (en) Solid-phase synthesis method of abaloparatide
US20220033440A1 (en) An improved process for the preparation of plecanatide
US9150615B2 (en) Process for the preparation of leuprolide and its pharmaceutically acceptable salts
US7176282B1 (en) Solid-phase peptide synthesis and agent for use in such synthesis
EP3398959B1 (en) Method for preparing lixisenatide
CN107556363B (en) Peptide or salt thereof and process for producing the same
US20230242581A1 (en) Synthesis of a guanylate cyclase agonist by fragments based approach
US20230406900A1 (en) Process for preparing glucagon-like peptide-1
TW202348620A (en) Process for preparing glucagon-like peptide-1
WO2011095989A2 (en) An improved process for the preparation of enfuvirtide

Legal Events

Date Code Title Description
AS Assignment

Owner name: SCINOPHARM TAIWAN LTD.,TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HSIAO, TSUNG YU;DING, JIN GUO;SIGNING DATES FROM 20090901 TO 20090904;REEL/FRAME:023589/0537

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION